Related Experiment Videos
Single-dose darbepoetin administration to anemic preterm neonates
Teresa L Warwood1, Robin K Ohls, Susan E Wiedmeier
1Intermountain Health Care, Neonatology Clinical Research Group, McKay-Dee Hospital, Ogden, UT 84403, USA.
Summary
Darbepoetin administration in preterm neonates accelerated red blood cell production. Findings suggest neonates may require higher doses and more frequent administration than adults.
Area of Science:
- Neonatal Medicine
- Pharmacology
- Hematology
Background:
- Darbepoetin is a longer-acting, more potent erythropoiesis-stimulating agent than recombinant erythropoietin (rEpo).
- Preterm neonates may benefit from erythropoietin therapy, but optimal darbepoetin dosing remains undetermined.
Purpose of the Study:
- To evaluate the safety and efficacy of single-dose subcutaneous darbepoetin in preterm neonates.
- To determine appropriate dosing and pharmacokinetic parameters for darbepoetin in this population.
Main Methods:
- A prospective trial involving 12 preterm neonates (<32 weeks gestation, <1500 g birth weight, >21 days old, Hgb ≤10.5 g/dl).
- Participants received a single subcutaneous dose of either 1 or 4 microg/kg darbepoetin.
- Immature reticulocyte fraction (IRF), absolute reticulocyte count (ARC), and pharmacokinetic parameters were measured.
Main Results:
- Both 1 and 4 microg/kg doses increased IRF and ARC, indicating accelerated erythropoiesis.
- Higher drug concentrations were observed in the 4 microg/kg group compared to the 1 microg/kg group.
- The drug's half-life (t1/2) was approximately 26 hours, with bioavailability-normalized clearance of 19 ml/hour/kg.
Conclusions:
- A single subcutaneous dose of darbepoetin effectively stimulates erythropoiesis in preterm neonates.
- Pharmacodynamic and pharmacokinetic data suggest that neonates may require higher unit doses and shorter dosing intervals than adults.